Aerovate Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Aerovate Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q3 2021 to Q3 2024.
  • Aerovate Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $259K, a 63.7% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $259K -$454K -63.7% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $621K -$190K -23.4% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $725K -$183K -20.2% Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $614K -$389K -38.8% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 $713K -$381K -34.8% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $811K -$377K -31.7% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $908K +$409K +82% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $1M +$461K +85.1% Dec 31, 2022 10-K 2024-03-25
Q3 2022 $1.09M +$511K +87.7% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $1.19M Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $499K Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $542K Dec 31, 2021 10-K 2023-03-29
Q3 2021 $583K Sep 30, 2021 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.